Lv5
992 积分 2023-04-11 加入
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
9天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
9天前
已完结
De Novo Design and Directed Evolution Refinement of Mirror‐Image Protein Binders Targeting Interleukin‐4
1个月前
已完结
Evaluating generalization in protein–ligand cofolding methods
2个月前
已完结
Novel Cyclic Peptides Inhibiting Tumor Necrosis Factor Receptor 1 Activity
5个月前
已完结
Computational design of superstable proteins through maximized hydrogen bonding
6个月前
已完结
AI-directed formulation strategy design initiates rational drug development
8个月前
已完结
AlphaFold3 for Noncanonical Cyclic Peptide Modeling: Hierarchical Benchmarking Reveals Accuracy and Practical Guidelines
9个月前
已完结
Design and synthesis of potent myostatin inhibitory cyclic peptides
10个月前
已完结
De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy
10个月前
已完结
皖公网安备34019202002308
